Prognostic histological markers in oral tongue squamous cell carcinoma patients treated with (chemo)radiotherapy.
Oral cancer
chemoresistance
high-endothelial venules
hypoxia-inducible factor-1 alpha
octamer-binding transcription factor 4
prognostic marker
radioresistance
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
17
10
2022
accepted:
19
01
2023
pubmed:
26
1
2023
medline:
14
3
2023
entrez:
25
1
2023
Statut:
ppublish
Résumé
Treatment of oral tongue squamous cell carcinoma (OTSCC) frequently includes surgery with postoperative radiotherapy (RT) or chemoradiotherapy (CRT). Resistance to RT or CRT remains a major clinical challenge and highlights the need to identify predictive markers for it. We included 71 OTSCC patients treated with surgery combined with RT or CRT. We evaluated the association between tumor budding, tumor-stroma ratio (TSR), depth of invasion (DOI), tumor-infiltrating lymphocytes (TILs), hypoxia-inducible factor-1alpha (HIF-1alpha) expression, octamer-binding transcription factor 4 (OCT4) expression, high-endothelial venules (HEVs), and disease-free survival (DFS) using uni- and multivariate analyses. No significant association was observed between the different histological and molecular markers (TSR, DOI, TILs, HEV, HIF-1alph, OCT4) and DFS. However, an associative trend between DOI, budding, and DFS was noted. Further studies with larger cohorts are needed to explore the prognostic value of DOI and budding for OTSCC patients treated with postoperative RT or CRT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
142-151Informations de copyright
© 2023 Scandinavian Societies for Pathology, Medical Microbiology and Immunology.
Références
Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4-5):309-16.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
Omura K. Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma. Int J Clin Oncol. 2014;19(3):423-30.
Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer. 2011;105(5):628-39.
Hartner L. Chemotherapy for oral cancer. Dent Clin N Am. 2018;62(1):87-97.
Barker HE, Patel R, McLaughlin M, Schick U, Zaidi S, Nutting CM, et al. CHK1 inhibition Radiosensitizes head and neck cancers to paclitaxel-based chemoradiotherapy. Mol Cancer Ther. 2016;15(9):2042-54.
Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409-25.
Wang C, Liu XQ, Hou JS, Wang JN, Huang HZ. Molecular mechanisms of chemoresistance in oral cancer. Chin J Dent Res. 2016;19(1):25-33.
Cadoni G, Giraldi L, Petrelli L, Pandolfini M, Giuliani M, Paludetti G, et al. Prognostic factors in head and neck cancer: a 10-year retrospective analysis in a single-institution in Italy. Acta Otorhinolaryngol Ital. 2017;37(6):458-66.
Hadjiiski L, Mukherji SK, Ibrahim M, Sahiner B, Gujar SK, Moyer J, et al. Head and neck cancers on CT: preliminary study of treatment response assessment based on computerized volume analysis. AJR Am J Roentgenol. 2010;194(4):1083-9.
Farsi NJ, Rousseau MC, Schlecht N, Castonguay G, Allison P, Nguyen-Tan PF, et al. Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol. Carcinogenesis. 2017;38(12):1188-95.
Liu SA, Wang CC, Jiang RS, Lee FY, Lin WJ, Lin JC. Pathological features and their prognostic impacts on oral cavity cancer patients among different subsites - a singe institute's experience in Taiwan. Sci Rep. 2017;7(1):7451.
Shimizu S, Miyazaki A, Sonoda T, Koike K, Ogi K, Kobayashi JI, et al. Tumor budding is an independent prognostic marker in early stage oral squamous cell carcinoma: with special reference to the mode of invasion and worst pattern of invasion. PLoS One. 2018;13(4):e0195451.
Almangush A, Pirinen M, Heikkinen I, Mäkitie AA, Salo T, Leivo I. Tumour budding in oral squamous cell carcinoma: a meta-analysis. Br J Cancer. 2018;118(4):577-86.
Sundquist E, Kauppila JH, Veijola J, Mroueh R, Lehenkari P, Laitinen S, et al. Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups. Br J Cancer. 2017;116(5):640-8.
Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393-410.
Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006;70(5):1469-80.
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-32.
Zhou J, Huang S, Wang L, Yuan X, Dong Q, Zhang D, et al. Clinical and prognostic significance of HIF-1α overexpression in oral squamous cell carcinoma: a meta-analysis. World J Surg Oncol. 2017;15(1):104.
Koo BS, Lee SH, Kim JM, Huang S, Kim SH, Rho YS, et al. Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells. Oncogene. 2015;34(18):2317-24.
Wang G, Zhou H, Gu Z, Gao Q, Shen G. Oct4 promotes cancer cell proliferation and migration and leads to poor prognosis associated with the survivin/STAT3 pathway in hepatocellular carcinoma. Oncol Rep. 2018;40(2):979-87.
Ventelä S, Sittig E, Mannermaa L, Mäkelä JA, Kulmala J, Löyttyniemi E, et al. CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance. Oncotarget. 2015;6(1):144-58.
Mishra S, Tiwari V, Arora A, Gupta S, Anand N, Husain N. Increased expression of Oct4, Nanog and CD24 predicts poor response to chemo-radiotherapy and Unfavourable prognosis in locally advanced Oral squamous cell carcinoma. Asian Pac J Cancer Prev. 2020;21(9):2539-47.
Jones E, Gallimore A, Ager A. Defining high endothelial venules and tertiary lymphoid structures in cancer. Methods Mol Biol. 2018;1845:99-118.
Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011;71(17):5678-87.
Ager A, May MJ. Understanding high endothelial venules: lessons for cancer immunology. Onco Targets Ther. 2015;4(6):e1008791-1.
Wirsing AM, Ervik IK, Seppola M, Uhlin-Hansen L, Steigen SE, Hadler-Olsen E. Presence of high-endothelial venules correlates with a favorable immune microenvironment in oral squamous cell carcinoma. Mod Pathol. 2018;31(6):910-22.
Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.
Almangush A, Leivo I, Siponen M, Sundquist E, Mroueh R, Mäkitie AA, et al. Evaluation of the budding and depth of invasion (BD) model in oral tongue cancer biopsies. Virchows Arch Int J Pathol. 2018;472(2):231-6.
Heikkinen I, Bello IO, Wahab A, Hagström J, Haglund C, Coletta RD, et al. Assessment of tumor-infiltrating lymphocytes predicts the behavior of early-stage oral tongue cancer. Am J Surg Pathol. 2019;43(10):1392-6.
Almangush A, Heikkinen I, Bakhti N, Mäkinen LK, Kauppila JH, Pukkila M, et al. Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers. Histopathology. 2018;72(7):1128-35.
Almangush A, Coletta RD, Bello IO, Bitu C, Keski-Säntti H, Mäkinen LK, et al. A simple novel prognostic model for early stage oral tongue cancer. Int J Oral Maxillofac Surg. 2015;44(2):143-50.
Wirsing AM, Rikardsen OG, Steigen SE, Uhlin-Hansen L, Hadler-Olsen E. Presence of tumour high-endothelial venules is an independent positive prognostic factor and stratifies patients with advanced-stage oral squamous cell carcinoma. Tumour Biol. 2016;37(2):2449-59.
Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, et al. Radioresistance in head and neck squamous cell carcinoma: biological bases and therapeutic implications. Head Neck. 2015;37(5):763-70.
Zhou Y, Zhang L, Pan H, Wang B, Yan F, Fang X, et al. Bmi1 essentially mediates podocalyxin-enhanced cisplatin chemoresistance in oral tongue squamous cell carcinoma. PLoS One. 2015;10(4):e0123208.
Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119-50.
Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6(1):209-17.
Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411(6835):375-9.
Xing Y, Zhao S, Zhou BP, Mi J. Metabolic reprogramming of the tumour microenvironment. FEBS J. 2015;282(20):3892-8.
Huang Y, Huang Q, Zhao J, Dong Y, Zhang L, Fang X, et al. The impacts of different types of radiation on the CRT and PDL1 expression in tumor cells under Normoxia and hypoxia. Front Oncol. 2020;10:1610.
Joseph JP, Harishankar MK, Pillai AA, Devi A. Hypoxia induced EMT: a review on the mechanism of tumor progression and metastasis in OSCC. Oral Oncol. 2018;80:23-32.
Xia Y, Jiang L, Zhong T. The role of HIF-1α in chemo−/radioresistant tumors. OncoTargets Ther. 2018;11:3003-11.
Oike T, Suzuki Y, Al-Jahdari W, Mobaraki A, Saitoh JI, Torikai K, et al. Suppression of HIF-1α expression and radiation resistance in acute hypoxic conditions. Exp Ther Med. 2012;3(1):141-5.
Tirpe AA, Gulei D, Ciortea SM, Crivii C, Berindan-Neagoe I. Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int J Mol Sci. 2019;20(24):6140.
Dellas K, Bache M, Pigorsch SU, Taubert H, Kappler M, Holzapfel D, et al. Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther Onkol Organ. 2008;184(3):169-74.
Bachtiary B, Schindl M, Pötter R, Dreier B, Knocke TH, Hainfellner JA, et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res. 2003;9(6):2234-40.
Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA, et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res. 2004 Dec 15;10(24):8405-12.
Kappler M, Taubert H, Holzhausen HJ, Reddemann R, Rot S, Becker A, et al. Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. Strahlenther Onkol. 2008;184(8):393-9.
Cai C, Wang J, Zhong Z, Dai Z, Wang Q, Dong W, et al. Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy. Zhejiang Xue Xue Bao Yi Xue Ban. 2017;46(1):36-43.
Silva P, Slevin NJ, Sloan P, Valentine H, Cresswell J, Ryder D, et al. Prognostic significance of tumor hypoxia inducible factor-1alpha expression for outcome after radiotherapy in oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2008;72(5):1551-9.
Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53(5):1192-202.
Swartz JE, Pothen AJ, van Kempen PMW, Stegeman I, Formsma FK, Cann EMV, et al. Poor prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinomas that overexpress hypoxia inducible factor-1α. Head Neck. 2016;38(9):1338-46.
Burdon T, Smith A, Savatier P. Signalling, cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol. 2002;12(9):432-8.
Siu A, Lee C, Dang D, Lee C, Ramos DM. Stem cell markers as predictors of oral cancer invasion. Anticancer Res. 2012;32(4):1163-6.
Ravindran G, Sawant SS, Hague A, Kingsley K, Devaraj H. Association of differential β-catenin expression with Oct-4 and Nanog in oral squamous cell carcinoma and their correlation with clinicopathological factors and prognosis. Head Neck. 2015;37(7):982-93.
Koukourakis MI, Giatromanolaki A, Tsakmaki V, Danielidis V, Sivridis E. Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer. 2012;106(5):846-53.
Sawant S, Gokulan R, Dongre H, Vaidya M, Chaukar D, Prabhash K, et al. Prognostic role of Oct4, CD44 and c-Myc in radio-chemo-resistant oral cancer patients and their tumourigenic potential in immunodeficient mice. Clin Oral Investig. 2016;20(1):43-56.
Routila J, Qiao X, Weltner J, Rantala JK, Carpén T, Hagström J, et al. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma. Oral Oncol. 2022;127:105772.
Milutinovic S, Abe J, Godkin A, Stein JV, Gallimore A. The dual role of high endothelial venules in cancer progression versus immunity. Trends Cancer. 2021;7(3):214-25.
Asrir A, Tardiveau C, Coudert J, Laffont R, Blanchard L, Bellard E, et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 2022;40(3):318-34.e9.
Kuwabara S, Tsuchikawa T, Nakamura T, Hatanaka Y, Hatanaka KC, Sasaki K, et al. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Cancer Sci. 2019;110(6):1853-62.
Wahab A, Onkamo O, Pirinen M, Almangush A, Salo T. The budding and depth of invasion model in oral cancer: a systematic review and meta-analysis. Oral Dis. 2022;28(2):275-83.
Bello IO, Wennerstrand PM, Suleymanova I, Siponen M, Qannam A, Nieminen P, et al. Biopsy quality is essential for preoperative prognostication in oral tongue cancer. APMIS. 2021;129(3):118-27.